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Abstract.—Cancer is a somatic evolutionary process characterized by the accumulation of mutations, which contribute to
tumor growth, clinical progression, immune escape, and drug resistance development. Evolutionary theory can be used
to analyze the dynamics of tumor cell populations and to make inference about the evolutionary history of a tumor from
molecular data.We review recent approaches tomodeling the evolution of cancer, including population dynamicsmodels of
tumor initiation and progression, phylogenetic methods to model the evolutionary relationship between tumor subclones,
and probabilistic graphicalmodels to describe dependencies amongmutations. Evolutionarymodeling helps to understand
how tumors arise and will also play an increasingly important prognostic role in predicting disease progression and the
outcome of medical interventions, such as targeted therapy. [Cancer; cancer progression; evolution; population genetics;
probabilistic graphical models]
Cancer is a very heterogeneous disease. Genetic
differences between people lead to differences in
susceptibility (Pharoah et al. 2004), tumors develop
in different organs and tissues of the body (Weinberg
2013), and cancers deriving from the same tissue can
be stratiﬁed into disease subtypes based on differences
in genomic measurements (Curtis et al. 2012). The
genetic heterogeneity among cancer cells and the
cellular heterogeneity of the tumor tissue underlie this
phenotypic heterogeneity of the disease. The cancer cells
in a tumor are not all identical, but form different clones,
deﬁned as sets of cancer cells that share a common
genotype. Genetic and epigenetic heterogeneity poses
a problem for the diagnosis and therapy of cancer. For
example, it can lead to incorrect treatment decisions if
a biopsy sample is not representative of other parts of
the tumor (Merlo et al. 2006). In addition, tumor cells
are part of the so-called tumor microenvironment, a
heterogeneous tissue containing not only cancer cells,
but also stromal and immune cells (Albini and Sporn
2007).
Cancer is an evolutionary process.—Despite the
heterogeneity of tumors, some functional organizing
principles exist, often summarized as the hallmarks
of cancer, which include evasion of apoptosis and
immune response, unstable DNA, and the ability to
metastasize (Hanahan and Weinberg 2000; 2011). A
particular successful guide for understanding and
modeling cancer progression has been evolutionary
theory, which has a long tradition in cancer research.
Already 40 years ago, seminal work established an
evolutionary view of cancer (Nowell 1976; Dexter
et al. 1978; Fidler 1978), in which carcinogenesis is
regarded as an evolutionary process driven by stepwise
somatic mutations and clonal expansions (Fig. 2a).
Within each tumor, clones can evolve that harbor
selectively advantageous mutations (called drivers),
neutral mutations (called passengers), and deleterious
mutations. The frequencies of passenger mutations
can rise in a population by chance, often because they
are linked to a driver mutation and hitchhike on the
expanding clone. Some mutations increase the rate
of other genetic changes and microenvironmental
changes can also alter the ﬁtness effects of mutations
(Greaves and Maley 2012; Barcellos-Hoff et al. 2013).
Moreover, there is evidence of competition, predation,
parasitism, and mutualism between co-evolving clones
in and around a tumor (Merlo et al. 2006). Most of
these concepts were known for decades when advanced
genomic technologies renewed interest in cancer
evolution in the early 2000’s. In the last few years,
next-generation sequencing (NGS) of cancer genomes
(Stratton et al. 2009) brought additional vigor to the
ﬁeld and has made tumor evolution a central topic in
cancer research (Greaves and Maley 2012).
Features of cancer evolution.—Evolutionary theory
is well developed and it provides an extensive
toolkit for any evolutionary process. Modeling the
somatic evolution of cancer also beneﬁts greatly from
this body of work. However, cancer evolution has
several speciﬁc features, including the following four.
(i) Cancer genomes harbor complex alterations. Many
tumors display genetic instability, which results in
abnormal numbers of chromosomes, that is aneuploidy
(Weinberg 2013), elevated mutation rates, and altered
distributions of mutational patterns (Garraway and
Lander 2013). In addition, some genomic alterations
can be extremely complex and rearrange entire
chromosomes. These alterations enable largemutational
jumps and they render comparisons between cancer
e1
 at U
niversity of Cam
bridge on M
arch 26, 2015
http://sysbio.oxfordjournals.org/
D
ow
nloaded from
 
[14:07 8/12/2014 Sysbio-syu081.tex] Page: e2 e1–e25
e2 SYSTEMATIC BIOLOGY VOL. 64
genomes challenging. (ii) There are many selectively
advantageous mutations. Recent cancer genome
sequencing studies have identiﬁed hundreds of driver
mutations (Vogelstein et al. 2013). Many of them disrupt
cellular signaling pathways that are essential for
multicellular organisms and may have occurred early
in the evolution of multicellularity. These pathways
tightly control and orchestrate cellular behavior in a
tissue. In general, there are many ways to perturb a
signaling pathway and hence, many possible mutations
exist that increase the somatic ﬁtness of cancer cells.
In this sense, cancer evolution can be regarded as the
evolution of defection (Nowak 2006a). (iii) Tumor cells
are organized in speciﬁc structures. Population structure
can result from interactions with the environment and
from the spatial organization or the differentiation
hierarchy of the tissue of origin. These structures affect
the fate of mutations that occur in individual cells
of the population, and hence the dynamics of tumor
progression (Nowak et al. 2003). (iv) Tumorigenesis
is a reproducible evolutionary process. Each tumor
of the same type, or subtype, can be regarded as an
independent realization of the same evolutionary
process, even if some confounding factors will remain,
for example, genetic background or microenvironment.
Repeated observations provide an opportunity to
enhance statistical inference about the evolution of
tumors, which may eventually make cancer evolution
more predictable (Orr 2005).
The evolutionary theory of cancer has survived 40
years of empirical observation and testing, and its
components are well understood. However, at the
same time, central questions remain controversial, for
example, the argument of gradualismversuspunctuated
equilibrium, which is a long-standing debate also in
species evolution (Gould and Eldredge 1993). The
cancer community currently actively discusses whether
tumors evolve gradually through a sequence of genetic
alterations and clonal expansions that accumulate
genomic lesions, or through a few punctuated changes
drivenby complex rearrangements (Baca et al. 2013; Shen
2013) or individual catastrophic events that shatter entire
chromosomes (Stephens et al. 2011). In addition, large
territories of cancer evolution still remain unexplored.
For example, the evolutionary dynamics of cancer are
still incompletely understood, becausemany parameters
of this process have not yet been or can generally not
be assessed experimentally, including ﬁtness effects of
mutations, generation times, population structure, the
frequency of selective sweeps, and the selective effects
of therapies (Merlo et al. 2006).
Controlling cancer evolution.—Research into cancer
evolution not only addresses basic biological questions
of tumor development and progression, but is also
of clinical signiﬁcance. For example, drug resistance
is a major clinical problem resulting in therapeutic
failureanduncontrolleddiseaseprogression.Evenwhen
patients initially respond well to cancer treatment,
they often die because their tumors develop resistance
to all available therapeutic avenues (Garraway and
Jänne 2012). In his (1976) landmark article, Nowell
wrote that “more research should be directed towards
understanding and controlling the evolutionary process
in tumors before it reaches the late stage seen in clinical
cancer.” This statement is as true now as it was 40
years ago. A recent literature survey found that even
though relapse and therapeutic resistance are inherently
evolutionary processes, evolutionary concepts have not
yet permeated cancer research (Aktipis et al. 2011),
emphasizing the great need for evolutionary approaches
to cancer biology and treatment.
Tumor heterogeneity and evolution as well as its
clinical implications have been reviewed recently and
extensively (de Bruin et al. 2013; Bedard et al. 2013;
Klein 2013; Junttila and de Sauvage 2013; Burrell et al.
2013; Meacham and Morrison 2013; Almendro et al.
2013; Aparicio and Caldas 2013; Greaves and Maley
2012; Marusyk et al. 2012; Caldas 2012; Podlaha et al.
2012; Lambert et al. 2011; Michor and Polyak 2010; Salk
et al. 2010; Bowtell 2010). In contrast to these biological
and medical reviews, we focus here on mathematical
andstatisticalmethodology formodeling tumorigenesis.
After reviewing the types of data available for
modeling the evolution of cancer, we discuss several
computational models, including population dynamics
models of cancer cells, phylogenetic methods of tumor
subclones, and probabilistic graphical models of tumor
progression. Cancer-speciﬁc terminology used in this
article is explained in Table 1.
MOLECULAR CANCER DATA
The amount and the breadth of tumor molecular
proﬁling has increased tremendously in recent years,
mainly due to the advent of cost-effective high-
throughput seqeuncing technologies. Genomic data
on cancer stems from a variety of different sources,
including (i) cell lines cultivated in laboratories, (ii)
xenografts derived from patient tumors and engrafted
into model organisms like mice, and (iii) clinical
patient samples from biopsies. Experimentally, cell
lines have several advantages over clinical samples:
Initially they are genetically homogeneous, they can
be kept under constant environmental conditions,
and they show no contamination with normal cells.
However, freed from its natural cellular context, this
evolutionary process can have little in common with
disease progression in patients, where, for example, the
tissuemicroenvironment affects tumor evolution (Bissell
and Hines 2011). Recent work on sequencing HeLa cells
has shown that cancer cell lines can evolve to be very
divergent and might be poor model systems for the
disease theywere derived from (Landry et al. 2013; Adey
et al. 2013). Xenografts, although more closely related to
a real tumor, are affected by different immune response
and microenvironment in the host, but they can model
tumor progression in a living organism over time with
little sampling restrictions (Hidalgo et al. 2014).
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TABLE 1. A table of common terms and acronyms used in cancer genomics
Term Description
aCGH Array CGH; microarray-based high-resolution CGH method
APC Adenomatous polyposis coli; a human tumor suppressor gene (TSG)
Allele frequency Fraction of cells (in NGS data, of reads) carrying a mutation
Aneuploidy Abnormal number of (parts of) chromosomes (Fig. 1)
BAF B allele frequency; ratio of the number of B alleles over the total (A+B) DNA content
BRAF Gene coding for the B-Raf protein, a signal transduction kinase that can be involved in cancer if mutated
Carcinogenesis The process of cancer development
Cellularity The proportion of tumor cells in a sample
CGH Comparative genome hybridization; cytogenetic method for analyzing copy number variations (CNVs)
Chromothripsis The shattering of the genome in one catastrophic event (Fig. 1)
Chromoplexy Chained rearrangement across several chromosomes (Fig. 1)
Clone A set of tumor cells descending from the same ancestor and hence sharing its mutations
Clonal frequency Percentage of tumor cells carrying an allele
CNV Germline (normal) copy number variation in normal cells of the tissue and in tumor cells
CNA Somatic copy number aberration (or alteration) in the cancer genome of tumor cells (Fig. 1)
Driver mutation Mutation that confers a selective advantage
EGFR Epidermal growth factor receptor; a cell-surface receptor whose altered expression is involved in cancer
Kataegis Local hypermutation; many SNVs clustered on a short genomic segment (Fig. 1)
LOH Loss of heterozygosity; Loss of one parental allele with or without a copy number change.
logR Logarithmic intensity ratio of tumor and control DNA in an array CGH experiment.
NGS Next-generation sequencing; High-throughput sequencing technologies based on massively parallel
DNA ampliﬁcation and sequencing
Oncogene Gene that confers a selective advantage if hit by a gain-of-function mutation
Oncogenetic model A model of the dependencies of events (CNAs, SNVs) in cancer development (Fig. 6)
Passenger mutation Selectively neutral mutation
Phasing The assignment of genomic alterations to speciﬁc haplotypes (Fig. 5)
Phylogenetic model A model of the evolutionary relationship between different tumor samples from the same patient or
between clones from the same tumor (Fig. 6)
Segmentation The process of calling integer copy numbers from noisy logR values.
Somatic evolution Evolution within an organism
SNP Single nucleotide polymorphism; single base variant existing in the human population
(found in normal tissue and tumor)
SNV Single nucleotide variant; single base change that occurred in the tumor (Fig. 1)
TSG Tumor suppressor gene; gene that confers a selective advantage if hit by a loss-of-function mutation
Tumorigenesis The process of tumor development
Vascularization The process of establishing blood vessels
Clinical samples are more direct reﬂections of the
disease but incur logistic and scientiﬁc problems (Basik
et al. 2013). For example, collecting multiple samples
frompatients can introducebiases, becausepatientswith
either very good or very poor response often contribute
only few samples. Indeed, if the patient is cured after
surgery or chemotherapy, no follow-up samples will be
available, whereas in patients progressing very quickly,
surgery is sometimes not attempted or the patient may
succumb to the disease in short time. In addition, ethical
and technical restrictions hinder broad collection of
samples. A biopsy might be highly interesting from
a scientiﬁc perspective but medically not necessary.
Finally, clinical samples often suffer heavily fromnormal
cell contamination (low cellularity) and inﬁltration of
immune cells such as lymphocytes (Yuan et al. 2012).
The Complexity of Cancer Genomes and the Search for
Driver Genes
The normal human point mutation rate is 10−10 per
base pair per cell division (Kunkel and Bebenek 2000),
and this rate is elevated in many cancers, a phenomenon
termed mutator phenotype (Loeb 2001; 2011). Hence,
almost every cell division introduces a mutation, which
inevitably leads togeneticdiversity in everyproliferating
cell population. Cancer genomes are characterized by
complex aberrations and rearrangements, ranging from
small-scale point mutations (single-nucleotide variants;
SNVs), often numbering in thousands per cancer cell,
to large-scale chromosomal rearrangements resulting
in complex patterns of genomic architecture and copy
number aberrations (CNAs) (Greenman et al. 2012;
Garraway and Lander 2013). Figure 1 gives an overview
of genomic changes widespread in cancer. In addition,
cancer genomes show epigenetic alterations, such as
changes to DNA methylation (Hong et al. 2010; Sottoriva
et al. 2013b). Some aberrations, like ampliﬁcations,
deletions, and point mutations, are also common to
many other evolutionary processes outside of cancer.
Others, such as chromosomal deletions where one
copy of a chromosome region is lost, are central
to explanations of cancer evolution like the two-hit
hypothesis (Nordling 1953).
In the following, we highlight complex patterns of
aberrations that have recently been discovered in cancer
genomes and whose evolutionary role is currently
being discussed. Kataegis refers to a pattern of localized
hypermutation, that is regional clusteringof substitution
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Kataegis 
localized hyper-mutation
Single nucleotide variant
heterozygous homozygous
Duplication
Tandem Interspersed Intra- and inter-chromosomal
Inversion
Translocation
Intra-chromosomal Inter-chromosomal
Chromoplexy
Inter-chromosomal chain
Chromothripsis
Intra-chromosomal
Deletion
TerminalInterstitial
Whole genome duplication 
Breakage Fusion Bridge
Loss of heterozygosity
Complex aberrations in cancer genomes
copy-number
neutral
loss of region focal
deletion
FIGURE 1. Common aberrations in cancer genomes. These events lead to the abnormal chromosome numbers (aneuploidy) and chromosome
structures of a cancer genome. Lines indicate the genome with germline genome on top and cancer genome with somatic aberrations below.
Double lines are used when differentiating heterozygous and homozygous changes is useful. Dots represent single nucleotide changes, whereas
lines and arrows represent structural changes.
mutations, observed in breast cancer genomes (Nik-
Zainal et al. 2012a). Breakage-fusion-bridge cycles lead
to palindromic genomic patterns, which can be an
early step in DNA ampliﬁcation (Guenthoer et al.
2012). Chromothripsis (chromosome shattering) refers to
a single catastrophic event in which tens to hundreds
of genomic rearrangements occur at the same time
(Stephens et al. 2011). Although its exact cause is
unclear, it is thought to be provoked by radiation
exposure at a critical time point during cell cycle when
chromosomes are condensed for mitosis. Cells that
survive the catastrophe can have a selective advantage
due to increased tumor cell growth, and their genomes
often exhibit CNA patterns oscillating between one and
two copies in the chromothriptic region. Chromoplexy is
a process similar to chromothripsis in that it involves
multiple genomic rearrangement events (Baca et al.
2013). The events often occur in a chain-like fashion
connecting spatially distant areas of the genome that
can affect multiple drivers from the same pathway
at the same time despite their location on different
chromosomes. Both chromothripsis and chromoplexy
showrandombreakage and fusionof genomic segments,
but several features set them apart: Chromothripsis
displays hundreds of breakpoints clustered within
a single chromosome, whereas rearrangements in
chromoplexy are unclustered, usually number in the
tens, and include multiple chromosomes (Shen 2013).
Chromothripsis appears to be a single catastrophic event
early in tumor progression, whereas chromoplexy can
occur multiple times during cancer evolution and has
beendetected at the clonal and subclonal level (Baca et al.
2013).
The complexity of cancer genomes and the presence
of mutator phenotypes make it challenging to separate
driver from passenger mutations. To identify genes
under positive somatic selection, one can detect an
excess of nonsynonymous somatic mutations, that is,
a high dN/dS ratio, in cancer genome sequences.
The same genes are often under purifying selection
in intergenerational terms leading to a depletion
of nonsynonymous polymorphisms in the human
population. Based on the idea of a high somatic dN/dS,
(Greenman et al. (2006)) formulated a hypothesis test in
a Poisson regression framework for discovering cancer
driver genes, which was applied to identify 120 driver
genes among 518 protein kinases in a cohort of 210 cancer
samples (Greenman et al. 2007). More recent methods
incorporate additional covariates, such as replication
timing and gene expression data to reﬁne estimates of
the local mutation rate (Lawrence et al. 2013). Gonzalez-
Perez et al. (2013) also accounted for the functional
impact of mutations, as predicted, for example, by SIFT
(Kumar et al. 2009) and PolyPhen2 (Adzhubei et al.
2010). In addition, they used evolutionary sequence
conservation and clustering of mutations within each
gene to identify driver genes. Recently, Lawrence et al.
(2014) analyzed 4,742 cancers to present a list of
219 recurrently mutated cancer genes. As the authors
suggest, this list may grow further in the future, as many
driver genes are only infrequently mutated.
Intratumor Heterogeneity and the Detection of Subclonal
Alterations
It has long been known that tumors are composed
of multiple cellular subpopulations with different
genotypes (Nowell 1976), and modern genomic
techniques have reﬁned this observation (Burrell et al.
2013). Analyzing single cells is the most informative
approach to assess the heterogeneity within a tumor.
Cell sorting can be used to detect cellular phenotypic
heterogeneity in blood cancers (Amir et al. 2013) and
immunoﬂuorescence in situ hybridization to highlight
the genetic diversity of individual loci (Almendro et al.
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2014). Progress in single-cell genomics (Shapiro et al.
2013) allows sequencing genomes of individual cells
taken from a tumor (Navin et al. 2011; Hou et al. 2012;
Xu et al. 2012; Potter et al. 2013). However, in most
studies, the samples used are a mixture of cancer cells
and stromal cells. In the following, we discuss how to
analyze clonal architecture from genomic proﬁles of
mixed samples.
Genomic data is typically obtained byNGSor byDNA
microarrays. Sequencing has the advantage of being able
to detect somatic SNVs as well as local tumor copy
numbers by read depth analysis. By contrast, SNP arrays
generally do not allow de novo discovery of SNVs, but
the SNP probes allow for allele-speciﬁc copy number
inference by considering bi-allelic frequency, that is,
the ratio of the frequencies of the two parental alleles.
The main objective when calling SNVs is to distinguish
sequencing errors from true variants and separating
germline from somatic changes. Algorithms solving this
problem either employ frequentist statistical methods
for modeling the distribution of variants per site in the
genome, suchasdeepSNV(Gerstunget al. 2012),Varscan
(Koboldt et al. 2012), and LoFreq (Wilm et al. 2012), or
employ a Bayesian classiﬁer framework, such as MuTect
(Cibulskis et al. 2013).
Classical methods for CNA calling, called
segmentation, are often ill-suited for cancer samples,
because they do not take differences in cellularity
nor changes in tumor ploidy into account. For those
methods that do, segmentation broadly follows the
same principles in most implementations: Normalized
array intensities or normalized read counts are deﬁned
as the log ratio, logR, between the local DNA copy
numbers in a mixture of cancer and normal cells and
the average copy numbers in the mixture,
logR= (n
A
i +nBi )+2(1−)
P+2(1−) (1)
Here,  is the cellularity, P is the average tumor ploidy to
which array intensities and read counts are normalized,
and nAi and n
B
i are the integer copy numbers of the two
parental alleles at locus i. The B allele frequency (BAF)
BAF= n
B
i
nAi +nBi
(2)
is the ratio between the B allele and the total allele count,
which can be obtained from both sequencing and SNP
arrays. It provides additional information about the copy
number state at a certaingenomic locus, as oftenonlyone
allele is ampliﬁed or deleted.
Traditionally, cellularity was assessed by visual
analysis of tumor cells, either manually by a pathologist
or via image analysis (Yuan et al. 2012). Laser capture
microdissection (Emmert-Buck et al. 1996) can be used
to select more homogeneous areas from mixed tissue
sections (Navin et al. 2010), but the procedure is time-
consuming and generally only used in small studies.
Most current methods for mixed samples estimate
both cellularity and average tumor ploidy during
segmentation, including PICNIC (Greenman et al. 2010),
ABSOLUTE (Carter et al. 2012), and ASCAT (Van Loo
et al. 2010). ASCAT calls copy numbers speciﬁcally for
each allele, which results in two integer vectors of copy
numbers, one for each parental allele. Because typically
no linkage informationbetweenadjacent loci is available,
at each site the larger of the two copy numbers, by
convention, deﬁnes the major and the smaller the minor
allele.
Unlike SNVs, where allelic frequencies can be directly
derived from read counts, CNA calling is difﬁcult
in populations with subclonal structure, because the
mixture of subclones leads to noninteger copy numbers
which introduce deviations from the expected log-ratio
(Equation 1) in array data or from the expected read
counts in sequencing data.
To address this issue, Oesper et al. (2013) proposed
THETA, an algorithm that infers the most likely
collection of genomes and their proportions from
NGS data, in the case where CNAs distinguish
subpopulations. Nik-Zainal et al. (2012b) introduced the
Battenberg algorithm (named after a checkered genomic
pattern resembling Battenberg cake), which ﬁrst assigns
all SNPs to known haplotypes, a task known as phasing.
Then it testswithinhaplotypeblocks for small deviations
of the BAF values (Equation 2) from those expected at
normal diploid loci to assess whether there is sufﬁcient
evidence for a subclonal copy number change.
POPULATION DYNAMICS OF CANCER CELLS
Population genetics provides a well-developed
mathematical theory of evolution (Durrett 2002; Ewens
2004), and many of these models and techniques have
been applied to cancer. The most basic models assume
no interactions among tumor cells and ignore any
structure of the population. These strong simpliﬁcations
result in mathematically tractable models that allow
for calculating quantities of interest such as intratumor
genetic diversity, the probability of ﬁxation of a new
mutant, or the age of the tumor. For this reason, models
of well-mixed populations with constant selection
are widely and successfully applied to the evolution
of cancer, and they provide the starting point for
more complex models. The population size, N, is an
important parameter affecting not only the evolutionary
dynamics of the population, but also the appropriate
choice of the mathematical model. In small populations,
allele sampling effects are more pronounced requiring
stochastic modeling, whereas large populations often
behave almost deterministically allowing for models
based on differential equations.
Historically, multistage theory was the ﬁrst approach
to model tumor progression based only on cancer
incidence data. Later, with the availability of protein
and DNA sequence data, classical population genetics
models of asexual populations have been applied to
tumorigenesis, and several new models have been
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FIGURE 2. Modeling the population dynamics of cancer cells. a) Schematic illustration of the genetic progression from initially healthy
cells (normal cells) to an invasive cancer by accumulating driver mutations. b) Age-incidence curves rise sharply above the age of 50 and are
informative about the dynamics of tumor progression. The straight line shows a ﬁt with power 4.8. The log-log-linear dependency of incidence
on age is used inmultistage theory to estimate the number of rate-limiting steps in cancer progression from incidence data. c) Population genetics
models such as the Wright–Fisher model can be used to model the accumulation of driver mutations through multiple clonal expansions and to
derive the average waiting times k for a given number of alterations k. d) Dynamics of a three-strategy game corresponding to cell types A, B,
and C. While simple additive ﬁtness models always lead to the survival of the ﬁttest, evolutionary game theory accounts for cellular interactions
and allows for more complex dynamics, such as stable coexistence of cell types. Indicated here is a stable equilibrium with strategy A and C, but
not B, which is reached from all three starting conditions via the indicated evolutionary paths.
developed to address speciﬁc aspects of the somatic
evolution of cancer. In this section, we ﬁrst review
classical multistage theory. Then, models are discussed
that are either stochastic or deterministic and assume
either a well-mixed or a structured population, followed
by hybrid models. Lastly, we address modeling of
cellular interactions using evolutionary games.
Multistage Theory
Multistage theory models the probability of
developing cancer as a function of age. The kinetics
of tumor initiation and progression are usually
unobserved, but different models can be tested and
parameters can be inferred by ﬁtting epidemiological
age-incidence curves. In 1953, Nordling observed that
cancer incidence rises sharply with higher ages and that
it can be approximated by a monomial in age of degree
six (Fig. 2b). Based on this observation, he postulated the
existence of six independent rate-limiting steps during
carcinogenesis. The underlying rationale of his inference
was the following: If a single transforming step towards
cancer occurs stochastically at a constant and small rate
u, then the probability to observe this transition after
time t is approximately ut. The cumulative probability
of k successive steps is therefore proportional to tk .
Although the transforming steps occur stochastically
in each patient, they will manifest on the population
level, which allows the number of rate-limiting steps
to be related to the observed age-incidence curves.
Armitage and Doll (1954) repeated Nordling’s analysis
one year later and estimated that the exponent of
the age-incidence curves ranged between 4.97 and
6.48 across a variety of cancer types. Using a similar
reasoning, Knudson (1971) attributed the differences in
the incidence of sporadic andhereditary retinoblastoma,
a childhood cancer of the eye, to the existence of two
independent rate-limiting mutations.
These early ﬁndings motivated the development of
the so-called multistage theory of carcinogenesis (Frank
2007), which predicts that cancer incidence, I, deﬁned as
the ﬁrst derivative of the cumulative number of cases,
depends on age t as
I(t)∝u1 ···uktk−1 (3)
where k is the number of stages and ui the transition
rate from stage i−1 to i. Multistage theory has been
extended to explicitly model the different kinetics of
tumor initiation, namely the acquisition of the ﬁrst
transforming mutation in a renewing tissue, and the
subsequent progression phases in the expanding tumor
(Armitage andDoll 1957; Luebeck andMoolgavkar 2002;
Calabrese et al. 2004; Meza et al. 2008; Luebeck et al.
2013). These stochasticmodelsusually require fewer rate-
limiting steps, as the rise in incidence is partly explained
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byexponential growth.Recently,multistagemodelshave
been used to optimize cancer screening strategies on the
population level (Jeon et al. 2008; Dewanji et al. 2011).
The existence of up to six rate-limiting steps in cancer
development has been widely accepted and appears
to resemble the prevalence of driver mutations found
in comprehensive cancer sequencing studies, where
estimates rangebetween twoandeight drivers per tumor
(Vogelstein et al. 2013).
Stochastic Models of Well-mixed Populations
The assumption of a well-mixed cancer cell
population, although questionable especially for
solid tumors, is frequently made, and the mathematical
approaches are best developed for this case. The most
basic models assume constant population size.
Moran process and Wright–Fisher process.—The Moran
process and the Wright–Fisher process are the standard
models for ﬁnite populations of constant size N. We
assume twodifferent cell types, referred toasnormal and
mutant (e.g., healthy and cancer cells, or two tumor cell
types with different mutational patterns), with ﬁtness
f1 and f2, respectively. The Moran process deﬁnes a
discrete-time Markov chain that keeps track of the
number ofmutants,X(t), in the population in generation
t (Moran 1958). In each step of the process, a cell is
randomly selected with probability proportional to its
ﬁtness to divide and produce one offspring, and another
cell is selected for death uniformly at random. Each
birth–death event leaves the total population size, N,
unchanged and can alter the number of mutants, X(t),
by at most one. The mutant subpopulation increases
if a mutant is selected for reproduction and a normal
cell for death. The probabilities of these two events are
proportional to f2X(t) and N−X(t), respectively. The
Moran process is the birth–death process deﬁned by
these transition probabilities. It has two absorbing states,
namely extinction (X=0) and ﬁxation (X=N) of the
mutant.
In case of neutral evolution (f1= f2), theMoran process
describes neutral drift of the population, that is, the
ﬂuctuation in allele frequencies due only to random
offspring sampling Kimura 1983. In this setting, the
probability of X mutants to reach ﬁxation is x=X/N.
If mutants have a selective advantage (f1< f2), then their
ﬁxation probability is
X = 1−(f2/f1)
−X
1−(f2/f1)−N
(4)
and the mean time to ﬁxation is (−2N)2[xlogx+
(1−x)log(1−x)] (Nowak 2006a). If u denotes the
mutation rate, then the total mutation rate in a tumor
of N cells is Nu and the rate of evolution, that is, the
rate at which the entire population shifts from normal
to mutant cells is Nu1. In the neutral case, the rate of
evolution is equal to the mutation rate, because then
1=1/N (Kimura 1983).
TheWright–Fisherprocess is very similar to theMoran
process, but in each generation, the entire population
is drawn at random from the previous generation
(Fisher 1930; Wright 1931). For two cell types and no
selection, it is deﬁnedby thebinomial sampling [X(t+1) |
X(t)] ∼ Binom(N, x(t)). Thus, cells are assumed to be
synchronized and one generation in the Wright–Fisher
process corresponds to N generations in the Moran
process. With this rescaling, both processes have the
same ﬁxation probability, (essentially) the same ﬁxation
time, and the same diffusion limit, that is, they agree in
the limit of large population size N→∞ (Ewens 2004).
For computer simulations, the Wright–Fisher process
generally allows drawing samples more efﬁciently.
When applied to cancer evolution, the Wright–
Fisher process has been generalized to multiple
cell types, representing genetically different tumor
subclones, using multinomial sampling, and it has been
extended to account for additional evolutionary forces,
including mutation, selection, and genetic instability
(Beerenwinkel et al. 2007a; Datta et al. 2013).
The coalescent.—The coalescent is a stochastic process
based on the Wright–Fisher process. It establishes
a connection to observed sequence data by making
inference about population parameters from a
contemporary ﬁnite sample. In the coalescent,
genealogies are generated by tracing coalescent events
between lineages backwards in time (Kingman 1982). In
the diffusion limit, N→∞, two lineages coalesce at rate( j
2
)
, when there are j individuals left (Rosenberg and
Nordborg 2002). The coalescent accounts for mutations
by imposing them on the random genealogy. It has
originally been developed for neutral evolution, but has
later been extended to account for selection (Neuhauser
and Krone 1997).
The coalescent allows for inferring characteristic
evolutionary parameters such as population size,
mutation rate, or the time to the most recent common
ancestor from sampled sequences. Nicolas et al. (2007)
apply the coalescent to DNA methylation patterns of
differentiated cells to estimate the number of stem
cells in a human colonic crypt, that is, the number
of cells at risk of initiating colon cancer. Statistical
inference in the coalescent can be computationally
demanding and several approximations to ML or
Bayesian estimation have been proposed, most notably
Approximate Bayesian Computation, which avoids
evaluation of the likelihood function (Marjoram et al.
2003; Haccou et al. 2005).
Branching processes.—Branching processes are well-
studied stochastic models for populations of ﬁnite, but
ﬂuctuating, size (Athreya and Ney 1972; Kimmel and
Axelrod 2002; Haccou et al. 2005). The basic assumption
is that individuals produce a random number of
offspring, each giving rise to an independent lineage
that behaves identically to its parent, that is, after a
certain lifetime, it will again produce a random number
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of offspring drawn from the same distribution. Most
branching processes are inherently unstable: Eventually,
the population will either die out or grow indeﬁnitely.
On the other hand, if a branching process with
constant lifetime (i.e., a Galton–Watson process) and
Poissonoffspringdistribution is conditionedon constant
population size, one obtains the Wright–Fisher process
(Haccou et al. 2005).
The probability generating function of the offspring
distribution is the main mathematical tool for
analyzing branching processes. It allows for computing
several quantities of interest, including the extinction
probability and time, and the probability of a mutant
to arise and to establish its lineage in the population.
For example, using a branching process with three
different cell types, Danesh et al. (2012) have modeled
ovarian cancer growth and progression, with the goal of
identifying a window of opportunity for screening, that
is, a timeperiodduringwhich tumordiagnosis is feasible
(tumor large enough), but treatment still possible (tumor
not progressed too far). Different tumor subclones can
be modeled by multitype branching processes, where
ﬁtness advantages translate into altered offspring
distributions. Because ﬁtness parameters are generally
unknown for cancer cells, Durrett et al. (2010) modeled
them as random variables. They studied the effect of
bounded versus unbounded ﬁtness distributions on
genetic tumor diversity and found that it depends only
on the maximum attainable ﬁtness advance, but not
on the speciﬁc form of the ﬁtness distribution (Durrett
et al. 2011).
The development of resistance to targeted cancer
treatment has been modeled by density-dependent
branchingprocesses.Here, tumor cell growth (andhence
offspring distribution) is limited by tumor size due
to geometric and metabolic constraints (Bozic et al.
2012). This modiﬁcation removes the instability of the
branchingprocess and introduces a steady state inwhich
the population size ﬂuctuates around a constant value.
The probability of tumor eradication under therapy can
be computed in thismodel by considering the generation
of resistance mutations during initial expansion, steady
state, and treatment.
Diffusion approximation.—Stochastic evolutionary
models can be approximated by differential equation
models to obtain simpler models that are more tractable
and easier to interpret. The diffusion approximation
is based on the assumption that the population size,
N, is large and that the change per generation is
small. It is given by the master equation, also called
Kolmogorov forward, or Fokker–Planck equation
(Fisher 1922; Kolmogorov 1931; Wright 1945; Feller
1951), for the probability density (x,t) of the relative
allele frequency x at time t in an evolutionary Markov
process X(t), as
∂(x,t)
∂t
=− ∂
∂x
M(x)(x,t)+ 1
2
∂2
∂x2
V(x)(x,t) (5)
The second-order differential operator depends only
on the mean M(x) and the variance V(x) of the
Markov process X(t). This framework allows for
analyzing or constructing evolutionary models with
speciﬁc directional (M) and undirectional (V) forces. For
example, at equilibriumof thediffusion limit (∂/∂t=0),
the Wright–Fisher process becomes
(x)∝x−1(1−x)−1ex (6)
where =2Nu and =2Ns are the scaled mutation
and selection parameters, respectively, and s= f2−f1
is the selective advantage of the ﬁtter allele. This
distribution reveals the strong impact of selection on
large populations and of random genetic drift on small
populations.
Tomasetti et al. (2013) used the diffusion
approximation of the Moran process to calculate
the expected number of passenger mutations that
accumulate in the precancer phase to be BuT, where
B is the total number of DNA bases sequenced, and
T the number of times the tissue has self-renewed
before tumor initiation. Using DNA sequencing data,
they found that at least half of all somatic mutations in
tumors of self-renewing tissues occur before the onset
of neoplasia.
Diffusion theory is also useful for computing ﬁxation
probabilities and mean ﬁxation times by considering
the conditional density (x,t |x(0)) (Ewens 2004). For
example, in the Wright–Fisher process, the ﬁxation
probability of a new mutant in a haploid population
is approximately 2s. The average ﬁxation time is
approximately 2Ns in the limit of weak selection,Ns1,
and2log(N−1)/s for strong selection (Otto andWhitlock
2001).
Tumor initiation and progression models.—Speciﬁc
evolutionary models have been proposed to describe
the dynamics of tumor initiation and progression. The
two basic genetic events driving carcinogenesis are
gain-of-function mutations in oncogenes and loss-of-
function mutations in tumor suppressor genes (TSGs).
Oncogenes are activated by speciﬁc point mutations,
gene ampliﬁcation, or chromosomal fusion. In a well-
mixed cell population of size N with constant mutation
rate u, to activate the oncogene the ﬁxation probability
by time t is
P(t)=1−exp(−Nu1t) (7)
where Nu1 is the rate of evolution (Michor et al.
2004). The equation shows that the accumulation of
oncogene-activating mutations is faster in large than
in small compartments. Thus, the organization of self-
renewing tissues into many small compartments, such
as, for example, the stem cell pools in colonic crypts,
from which the tissue is derived, protects against cancer
initiation.
The dynamics of TSG inactivation are more complex,
because here two alleles need to be hit, either by two
point mutations, or by one point mutation and loss of
heterozygosity (LOH). For simplicity,we assume that the
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ﬁrst hit does not confer any selective advantage. Then,
in small populations and for short time spans t, the TSG
ﬁxation probability P(t) is quadratic in t, indicating two
rate-limiting steps as in Knudson’s two-hit theory. In
intermediate populations, however, the secondmutation
may arise before the ﬁrst one has reached ﬁxation, a
phenomenon termed stochastic tunneling. As a result, in
intermediate populations, the TSGﬁxation probability is
linear in t. Finally, there is no rate-limiting step in large
populations (Nowak 2006a; Komarova 2007). Genetic
instability can result in elevated mutation rates, which
overall may or may not accelerate TSG inactivation,
depending on the rate at which genetic instability is
acquired and on the possible ﬁtness costs it incurs.
The initial tumor cell lives inahostile environment and
generally has several possibilities to accumulate driver
mutations to survive and expand. Using multitype
branching processes, the evolutionary escape dynamics
have been derived for arbitrary ﬁtness landscapes
deﬁned on any genotype network, that is, any set of
genotypes connected by mutation (Iwasa et al. 2003;
Iwasa et al. 2004). Assuming that the initial tumor cell
is too unﬁt to survive in the long run, the risk of escape
is the probability of the population developing, before
extinction, additional mutations that allow for escaping
the selective pressure. For a given genotype network, the
risk of escape is proportional to the per-site mutation
rates and to the polynomial
∑
i0→i1→···→ik
fi1 ···fik−1 (8)
in the ﬁtness values (Beerenwinkel et al. 2006). Here,
the sum runs over all possible mutational pathways
in the network from the initial and unﬁt genotype i0
to the escape type ik , where a mutational pathway
is a sequence of viable mutants. The risk polynomial
(Equation 8) captures the impact of the topology of
genotype space on evolutionary escape. The larger the
number of alternative escape pathways, the higher is the
risk of escape. Studies on protein evolution have shown
that only few mutational paths can lead to ﬁtter proteins
(Weinreich et al. 2006). Hence, understanding these
mutational constraints for the evolutionary escape of
cancer cells may make tumorigenesis more predictable.
During tumor progression, selectively advantageous
mutations give rise to clonal expansions, which drive
tumor growth. The series of selective sweeps is often
described as a sequence of traveling mutant waves
(Fig. 2c). To understand this process, mathematical
models have been devised that address questions about
the speed of evolution, the waiting time distribution,
and the clone size distribution (Park et al. 2010). They
are typically based on the Moran or the Wright–
Fisher process, and different approximations have been
proposed to arrive at the quantities of interest.
For example, assuming Wright–Fisher dynamics, the
average waiting time for the ﬁrst cell with k mutations to
appear in a population of size N has been approximated
as
k = k2s logN
(
log
s
ud
)2
(9)
where d is the number of driver genes, each of which
confers the selective advantage s (Beerenwinkel et al.
2007a). Thus, the waiting time is approximately linear
in the number of mutations and tumor progression
is driven mainly by selection. Schöllnberger et al.
(2010) have identiﬁed the successive clonal expansions
predicted by this model with the rate-limiting steps in
multistage theory.
The rough approximation (Equation 9) has been
reﬁned and generalized in several ways. Using a
branching process, Bozic et al. (2010) showed that in
a growing population, the acquisition of subsequent
driver mutations becomes increasingly faster. They
estimated the average selective advantage per driver
mutation from experimental data to be as small
as s≈0.004. In addition, the stochasticity of the
branching process provides an explanation for the huge
heterogeneity in tumor sizes and progression times
observed clinically. This model also allows for relating
the expected number of drivermutations, k, to passenger
mutations, n,
n= 	
2s
log
4ks2
u2
logk (10)
where 	 is the rate of acquisition of neutral mutations,
and u the driver mutation rate.
Durrett et al. (2009) considered a branching process
approximation of the Moran process to arrive, in
a rigorous analysis, at waiting times generalizing
Equation 9 and the results for TSG inactivation
(Durrett and Mayberry 2011). Furthermore, mutation
accumulation has also been studied in exponentially
growingcancer cell populations (Iwasaet al. 2006:Haeno
et al. 2007; Durrett and Moseley 2010). McFarland et al.
(2013) used a stochastic birth–death process to study
the effect of moderately deleterious, rather than neutral,
mutations on tumor progression and to explore cancer
treatments that exploit their genetic load. In an attempt
to calculate waiting times to cancer under mutational
order constraints, Gerstung and Beerenwinkel (2010)
considered conditionally independent Poisson waiting
times for each mutation and derived the waiting time,
k , accounting for all mutational pathways in genotype
space.
Models for the evolution of drug resistance.—The evolution
of drug resistance is frequently observed during cancer
treatment. For example, BRAF mutant melanomas
treated by a targeted inhibitor often acquire resistance
through mutations in other genes after initial response
(Nazarian et al. 2010). A classical model for testing
whether resistance is acquired during treatment or
caused by pre-existing subclones is the model of Luria
and Delbrück (1943). In their pioneering work on
resistance of bacteria to infection with a bacteriophage,
they calculated the relation between the mean and
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the variance of the number of drug resistant colonies
emerging in an exponentially growing population. If
resistance is acquired at the time of infection and cell-
speciﬁc, then the number of resistant clones follows
Poisson statistics, whereas the variance is larger if pre-
existing resistant clones are selected, because resistant
clones are not independent. Recently, Diaz Jr et al.
(2012) used this model to conclude that in colorectal
carcinomas, resistance to EGFR inhibitors, which is
frequent and occurs after a rather constant time of
treatment, is caused by pre-existing subclones. The
analysis of Goldie and Coldman (1979) demonstrated
that resistant subclones exist in a tumor with probability
proportional to tumor size and mutation rate. Bozic
et al. (2013) used branching processes to compute the
probability of mono- and combination therapy success
under the assumption that single mutations confer
resistance to an individual drug and showed that
combination therapy is much more likely to succeed.
Stochastic Models of Structured Populations
The evolutionary dynamics of structured populations
can differ from those in well-mixed populations.
Population structure may result from cell differentiation
into functional groups or from separation of cells into
spatial compartments. For example, the simplest form
of a regular grid is the n-dimensional lattice, where
the number of interaction partners is identical for all
cells. Komarova (2006, 2007) has shown that the ﬁxation
probability in the one-dimensional lattice is smaller than
in amixedpopulation, because thenumberof interaction
partners is constrained to the surrounding neighbors,
which suppresses the effect of selection.
Linear systems.—A simple one-dimensional system is
motivated by the colonic crypt, which is organized as
a vertical cylinder with a small number of stem cells at
the bottom and the colonic epithelium at the top end.
Stem cells divide slowly and produce differentiating
cells that move up the cylinder until they reach the
epithelium where they eventually shed off. Because of
its radial symmetry, this process can be idealized by a
linear chain of length N with a stem cell on one end
and the epithelium on the other end (Nowak et al. 2003).
As all but the stem cells are only transiently present
in this system, only mutations in the stem cell will
reach ﬁxation, thereby reducing the number of cells at
risk from N to just one. The process of shedding is
regulated by theAPC TSG,whose deactivation results in
the accumulation of cells and their outgrowth as polyps.
To inactivate both alleles of the tumor suppressor APC,
the stem cell needs to be hit at least once followed by a
second hit either in the stem cell or in a differentiating
cell, as a double mutation in a differentiating cell is
rather unlikely due to their short lifespan. The linear
architecture of the colonic crypt can also be modeled by
consecutive compartments of stem cells, differentiated
cells, and transit cells, in which tumor growth is caused
by imbalances between the rates of exchange between
these (Johnston et al. 2007). Recently Zhao and Michor
(2013) extended the linear process model to include
spatially different growth kinetics along the crypt and
found that the experimentally observed kinetics with an
increased proliferation rate closer to the stem cell at the
base of the crypt best suppressed the evolution of TSGs.
Cellular automata.—The replication dynamics of cells
on a discrete lattice in discrete time deﬁnes a cellular
automaton (Deutsch and Moreira 2002). Each cell
is represented by a separate object that stores the
position, movement, and cell identity. The movement
and replication dynamics are modeled by a set of
rules accounting for the cellular state and its response
to neighboring cells and microenvironmental stimuli.
Cellular automata have the advantage that the fate of
every cell is explicitly modeled. This imposes, however,
a large computational cost when large ensembles of
cells are simulated, and, in general, analytical results are
infeasible.
Thalhauser et al. (2010) analyzed 1D and 2D spatial
generalizations of the Moran process by including cell
migration. They found that migration has a positive
effect on the ability of a single mutant cell to invade a
pre-existing colony and that large-scale cell death selects
for the migratory phenotype. This ﬁnding may explain
how chemotherapy provides a selection mechanism for
highly invasive cancer cells.
Perfahl et al. (2011) proposed a complex 3D multiscale
model of tumorigenesis that accounts for vascularization
by coupling several processes, including blood ﬂow,
angiogenesis, nutrient and growth factor transport,
cell movement, and interactions between normal and
tumor cells. The agent-based model is analytically
intractable, but in forward simulations, the spatio-
temporal evolution of a vascular tumor can be
investigated, including its response to therapy.
Deterministic Models of Well-mixed Populations
In large well-mixed populations, stochastic effects can
be negligible such that deterministicmodels of evolution
basedondynamical systems canbe applied that describe
the mean behavior of the evolutionary system. Denoting
by xi the frequency of genotype i and by x˙i its derivative
with respect to time, the replicator equation (Schuster
and Sigmund 1983) is
x˙i=xi[fi(x)−
(x)], i=1,...,n (11)
where fi(x)= fi(x1,...,xn) denotes the ﬁtness which,
in general, depends on the frequencies of all other
genotypes. The term 
(x)=∑j fj(x)xj is the average
ﬁtness of the population. In the special case of constant
ﬁtness, fi(x)= fi, the replicator equation is termed
selection equation. In this case, the genotype with
highest ﬁtness reaches ﬁxation, whereas all others go
extinct; this is commonly referred to as survival of the
ﬁttest (Nowak 2006a). The selection equation can be
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extended to account for mutation with probability qij
from type i to type j to obtain the so-called quasispecies
equation x˙i=
∑
j xjfjqji−
(x)xi. This model predicts an
error threshold, that is, a critical mutation rate beyond
which thepopulationcannotbemaintaineddue to lossof
vital genetic information. Using this approach, Solé and
Deisboeck (2004) explored the effect of genetic instability
on tumor progression and found that an error threshold
exists in mutator phenotype cancer cell populations,
whereas Brumer et al. (2006) compared the effect of
microsatellite and chromosomal instability on tumors.
Deterministic Models of Structured Populations
At a macroscopic scale, the number of cancer cells in
a given volume may be approximated by a continuous
density. The continuum approximation of the dynamics
on regular grids is given by partial differential
equations (PDEs). A random spatial movement is then
approximated as diffusion and a directed movement by
physical drift (not to be confused with random genetic
drift). The solutions of PDEs canbe efﬁciently computed,
and in certain limit cases, there exist analytical solutions
or solutions that can be approximated by analytically
tractable models. The latter approaches have the
advantage that one can directly assess the inﬂuence of
certain model parameters (Murray 2002). PDEs have
been used to model the dynamics of tumor cell density
and its dependency on other diffusive factors such
as nutrients and growth factors. Many authors have
studied avascular tumor growth to elucidate the role
of nutrient ﬂux and necrotic signaling during early
tumor growth (Roose et al. 2007). Avascular tumor
growth is characterizedbyanearly exponential spherical
expansion up to a diameter of about 1mm, above which
cells on the inside becomenecrotic and growth saturates.
Population structure due to differentiation exists, for
example, in the hierarchically organized hematopoietic
system. It consists of a few thousand slowly replicating
hematopoietic stem cells which differentiate in multiple
steps into different mature blood cells. The evolutionary
dynamics of the average number of cells in a given stage
can be modeled by a system of ordinary differential
equations. Such models show that the hierarchical
organization suppresses the accumulation of mutations
and correctly predict the clonal diversity in childhood
acute lymphoblastic leukaemia (Werner et al. 2013).
The different rates of cellular proliferation in stem cells
and differentiating cells can also explain the biphasic
response to imatinib treatment in chronic myeloid
leukemia as well as the rates of relapse due to resistance
mutations (Michor et al. 2005).
Hybrid Models
Hybrid approaches of PDEs and cellular automata
have been used to model the discrete dynamics of cell
fates coupled to diffusive signals and nutrients ﬂuxes
(Anderson and Quaranta 2008). Dormann and Deutsch
(2002) used a hybrid cellular automaton to model the
avascular growth of tumor cells. Vascularization is a
hallmark of cancer, and vascular endothelial growth
factor (VEGF) signaling can be therapeutically targeted.
Alarcón et al. (2005) used a multiscale model for the
vascular tumor growth accounting for tumor-normal
cell interactions and vascularization through VEGF
signaling. Owen et al. (2009) used a similar model
to understand the dynamics of vascularization under
different drug pressures to optimize drug efﬁcacy.
A precise understanding of cancer growth kinetics
may help optimize surgery and therapy duration, and
eventually, quantitative models measuring the effect of
drugs could be used for ﬁnding optimal drug dosage.
Modeling Cellular Interactions using Evolutionary Games
Except for the replicator equation (Equation 11),
all models discussed above assume constant ﬁtness.
However, the somatic ﬁtness of cancer cells is
likely to be density-dependent, because tumor cells
interact with each other and with stromal cells (Poste
et al. 1981). Evolutionary game theory provides a
mathematical framework formodeling such interactions
(Maynard Smith 1982). Here, ﬁtness is the expected
outcome of a game, which is deﬁned by a payoff matrix.
The dynamics of an evolutionary game can be either
stochastic or deterministic and populations may be
structured or not.
When two different cell types, or strategies, i and j
meet and interact, then Mij denotes the payoff, that is,
the beneﬁt or harm, that cell type i receives from the
interaction. In a well-mixed population, the expected
payoff is a linear function of the population frequencies
xj, such that the ﬁtness of type i becomes
fi(x)=
∑
j
Mijxj (12)
For inﬁnite population size, the dynamics can be
modeled by the replicator equation (Equation 11). The
resulting dynamical behavior is much richer than in the
situation with constant ﬁtness, as it allows for multiple
stable equilibria with coexistence of different cell types
and for oscillatory patterns (Fig. 2d). In situations with
multiple equilibria, the ﬁxed point reached may also
depend on the initial composition of the population. In
the stochastic ﬁnite population size case, solutions of the
corresponding Moran process have been derived in the
limits of weak and strong selection (Taylor et al. 2004;
Fudenberg et al. 2006).
A prototype two-strategy game offering insights
into the evolution of cooperation and defection is
the Prisoner’s Dilemma (Axelrod and Hamilton 1981).
In this game, cooperators pay a cost for others to
achieve a beneﬁt. Defectors, however, do not pay this
cost, but nevertheless receive the beneﬁt when playing
against a cooperator. This leads to a situation where
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in the presence of co-operating cells a defector has a
higher expected payoff leading to a selective advantage.
The defecting strategy is the only evolutionarily stable
strategy as it is a Nash equilibrium of the game.
However, it does not maximize the overall population
ﬁtness as the payoff between two defectors is zero.
The Prisoner’s Dilemma game illustrates the somatic
evolutionary advantage of defecting tumor cells in
tissues of cooperative cells, which evolution generated
in multicellular organisms (Nowak 2006a). It also raises
the question under which conditions co-operativity
can evolve. These conditions include different levels of
reciprocity and group selection (Nowak 2006b).
Tumors consist of many cell types and interactions
may occur at different levels. Vascularization is one
hallmark of cancer, and tumor cells generally require the
support of other stromal cells. Tumor cells also compete
for resources, which introduces an interaction among
them. Evolutionary game theory allows for modeling
interactions between cancer and stromal cells and also
cooperation among tumor cell types. Tomlinson (1997)
has investigated the dynamics of multiple tumor cells
where one cell type produces a substance cytotoxic
to another and under which conditions a cytotoxic
cell type can spread through the tumor. Gatenby
and Vincent (2003) analyzed the evolution of cancer
cells under growth control mechanisms competing
for resources and found that such mechanisms can
lead to multiple coexisting tumor cell types. Similarly,
Axelrod et al. (2006) studied under which conditions
cooperation among tumor cells can evolve. Gerstung
et al. (2011b) investigated coexistence of multiple tumor
types interacting with stromal cells using afﬁne ﬁtness
functions, which include a constant ﬁtness contribution
in addition to the expected payoff. Due to the symmetry
of the replicator equation, the corresponding replicator
dynamics can be transformed to an equivalent game
with different payoff (Stadler 1991). Other applications
include the work by Dingli et al. (2009), who showed
that the phenotypic variability commonly observed in
multiple myeloma, a blood cancer, can be explained by
an evolutionarygame. Basanta et al. (2012) havemodeled
the dynamics of different prostate tumor strategies
and their interactions with stromal tissue and have
analyzed how the resulting dynamics can be inﬂuenced
by therapy.
TUMOR PHYLOGENY
The reconstruction of evolutionary trees is a classical
topic in computational and evolutionary biology with a
wealth of algorithms and models of sequence evolution
(Felsenstein 2003), and these methods can be applied
to the somatic evolution of cancer (Fig. 6a). Cancer
cells divide and accumulate mutations and genomic
rearrangements to form clonal subpopulations, the
taxa in the phylogenetic tree. Tumor phylogenies
represent the evolutionary history of its subclones
and can be used to test different hypotheses about
tumor evolution (Navin and Hicks 2010). However, the
speciﬁc features of tumor evolution and cancer data
pose challenges to the direct application of classical
phylogenetic models. For example, clinical samples
contain an unknown number of novel cancer genomes
with admixture of normal tissue, whereas classical
phylogenetic approaches assume that taxa are known
a priori. Additionally, short read NGS does not reveal
complete haplotypes, but only individual alterations
without information about their co-occurrence.
Many different types of data and cellular properties
have been used for evolutionary analyses in cancer,
including microsatellites (Frumkin et al. 2008) and
lentiviral barcoding (Nolan-Stevaux et al. 2013), but in
the following we mostly limit the discussion to SNVs
and CNAs, two widely used data types (Gerlinger
et al. 2012; Carlson et al. 2012). Inference from complex
events like chromothripsismight becomevery important
in the future, but currently only the basic concepts
have been described and robust inference methods to
identify these events are lacking (Korbel and Campbell
2013). We end the section with a short overview of the
current developments in single-cell sequencing, which
will provide new opportunities for tumor phylogeny
reconstruction in the future. For a summary of the
software discussed in this section, see Table 2.
Phylogenetic Tree Reconstruction from SNVs
Sequencing a population of cancer cells allows to
infer SNVs and their allele frequencies (Fig. 3). The
allele frequencies need to be corrected for copy number
alterations, LOH, and normal contamination to estimate
the percentage of cancer cells carrying the SNV (Shah
et al. 2012; Roth et al. 2014). Because it is unknown
in which genome a given SNV occurred, prior to tree
reconstruction, SNVs are clustered into sets ofmutations
with common frequency (Fig. 3d). This clustering is often
performed using Bayesian mixture models, either ﬁnite
ones (Larson and Fridley 2013) or nonparametric ones in
which the number of mixture components is estimated
together with their frequencies and densities (Shah et al.
2012; Nik-Zainal et al. 2012b; Roth et al. 2014).
For manual phylogenetic tree reconstruction from
inferred SNV frequencies, Nik-Zainal et al. (2012b)made
two assumptions: (i) no mutation occurs twice in the
course of cancer evolution (inﬁnite sites assumption),
and (ii) no mutation is ever lost (no back mutations).
These assumptions translate into two basic principles:
The pigeonhole principle or Dirichlet’s Box (Fig. 4a),
which in the simplest case states that if the sum of
the clonal frequencies of two SNVs is greater than
100%, at least one cell must have contained both SNVs.
Because the same mutation cannot be gained twice
independently by theﬁrst assumption, one clonemust be
the ancestor of the other. The second assumption implies
that the clone with the higher clonal frequency, that is,
the larger number of cells carrying the SNV, must be the
ancestor (Fig. 4b). These assumptions, although naive
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TABLE 2. Software tools implementing phylogenetic methods for reconstructing within-patient and within-tumor evolutionary tumor
histories.
Software Data Model / Inference References
PhyloSuba SNV Tree-stick-breaking process, binomial / MCMC (Adams et al. 2010)
PyCloneb SNV Dirichlet Process, beta-binomial / MCMC (Roth et al. 2014)
SciClonec SNV Beta mixture model Miller et al. 2014
Clomiald SNV Binomial / EM (Zare et al. 2014)
Trape SNV Exhaustive search under constraints (Strino et al. 2013)
CloneHDf SNV + CNA HMM, EM, Variational Bayes (Fischer et al. 2014)
ThetAg CNA Maximum likelihood (Oesper et al. 2013)
cancerTimingh CNA Maximum likelihood (Purdom et al. 2013)
GRAFTi CNA Partial maximum likelihood (Greenman et al. 2012)
MEDICCj CNA Finite state transducer, Minimum-event distance (Schwarz et al. 2014b)
TuMultk CNA Breakpoint distance (Letouzé et al. 2010)
TITANl CNA HMM / EM (Ha et al. 2014)
Notes: SNV, single-nucleotide variant; CNA, copy number aberration;MCMC,Markov-chainmonte carlo; EM, expectationmaximization; HMM,
Hidden Markov Model;
ahttps://github.com/morrislab/phylosub
bhttp://compbio.bccrc.ca/software/pyclone
chttps://github.com/genome/sciclone
dhttp://www.bioconductor.org/packages/devel/bioc/html/Clomial.html
ehttp://sourceforge.net/projects/klugerlab/ﬁles/TrAp
fhttps://github.com/andrej-ﬁscher/cloneHD
ghttps://github.com/raphael-group/THetA
hhttp://cran.r-project.org/web/packages/cancerTiming
ihttp://www.sanger.ac.uk/genetics/CGP/Software/GRAFT
jhttps://bitbucket.org/rfs/medicc
khttp://bioserv.rpbs.univ-paris-diderot.fr/ letouze/TuMult
lhttp://compbio.bccrc.ca/software/titan/
d)c) Mutation calling SNV frequencies
Most reads: 
single SNV
Very few reads: 
two SNVs
mutation frequencies [%]
Genome
b) Poly-clonal tumor
Clones Normal
a) Evolutionary tree
A
AB
A ABC ABD
70%
40%
Percentage of 
cells with SNVs
(out of all cells)
Set of SNVs
30%
23% 7%
707 23 30
AB CD
N
um
be
r o
f S
N
Vs
FIGURE 3. Inferring tumor phylogeny from next-generation sequencing data. a) Subclones are related to each other by an evolutionary
process of acquisition of mutations. In this example, the three clones (leaf nodes) are characterized by different combinations of the four single
nucleotide variant (SNV) sets A, B, C, and D. The percentages on the edges of the tree indicate the fraction of cells with this particular set of
SNVs, e.g., 70% of all cells carry A, 40% additionally carry B, and only 7% carry A, B, and D. b) The evolutionary history of a tumor gives rise
to a heterogeneous collection of normal cells (small discs) and cancer subclones (large discs, triangles, squares). Internal nodes that have been
fully replaced by their descendants (like the one carrying SNV sets A and B without C or D) are no longer part of the tumor. c) Sequencing data
consist of short reads covering (parts of) the cancer genome. Comparison to the germline DNA of the same patient allows to identify SNVs and
other genomic aberrations. Since reads are short, most will only cover a single SNV. In few cases, pairs of SNVs are covered, which allows to
assess patterns of co-occurrence and mutual exclusivity between SNVs. d) The sets of SNVs distinguishing the subclones cluster in the SNV
frequency distribution. The mean of each cluster (x-axis) is the fraction of cells carrying this set of SNVs. The goal of tumor phylogenetics is to
infer the evolutionary tree (a) from the mutations observed in the sequencing data (c) and their frequencies (d).
from a general phylogenetics perspective, appear to be
justiﬁed in the cancer setting. Recent sequencing efforts
showed that HeLa cells have accumulated about four
million SNVs (Adey et al. 2013). Even with such a large
number of mutations the probability of the same site
being affected twice is about 1/1000, assuming a uniform
mutation rate across the genome. Back mutations are
accordingly less likely.
Computational methods have been proposed that
implement these two rules. Strino et al. (2013) used a
linear algebra approach that makes use of parsimony
and sparsity assumptions to limit the number of possible
trees. They show that their approach works for up to
25 aberrations, which makes extensive feature selection
necessary, but it may be applied to the output of
the mixture models discussed above by treating each
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a) b) c)
FIGURE 4. Two simple principles for tree inference from SNVs. For a given set of subclones and their respective clonal fractions, each illustrated
by a triangle with a dot at the top vertex representing the clonal origin, two conditions need to be met for a potential phylogeny to be considered
feasible: a) Dirichlet’s box: If two SNV frequencies (small triangles inside large triangle) sum to more than 100%, then some cancer cells must
contain both SNVs (overlap of the two small triangles). In a tree-like evolutionary process some cells must have acquired the same mutation
independently, which in cancer, is considered highly unlikely. Hence, one of the two subclones (small triangles) is ancestral to the other. b) Larger
ancestor: In this case, if one clonal fraction is larger than the other, the larger must be the ancestor; otherwise cancer cells would have lost the
previously gained mutation (nonoverlapping regions between the two small triangles at the bottom), which again is considered highly unlikely.
The most likely feasible solution is shown in c), where both principles are met (and the two small triangles are nested).
cluster as a single aberration. However, Nik-Zainal et al.
(2012b) demonstrated the limitations of sequential SNV
clustering and tree reconstruction. In their analysis, one
of the clusters was spread over three different branches
of the tree. Such inconsistencies may be avoided by
combining clustering and tree reconstruction into a
single step. Recently, Zare et al. (2014) proposed a
generalization of the approach implemented by Strino
et al. (2013) to multiple samples per patient. Jiao et al.
(2014) present a joint approach based on interleaving two
stick-breaking processes, which results in a hierarchy of
clusters (Adams et al. 2010). A recent implementation
of a nonparametric Bayesian clustering approach that
implements those principles is the work of Roth et al.
(2014), which jointly infers posterior density estimates
overboth the clustering structure andcellularprevalence
of the clones using MCMC sampling. An alternative is
the work of Miller et al. (2014) which uses a variational
Bayesian mixture model for subclone identiﬁcation.
Finally, Fischer et al. (2014) make use of the combined
information in CNAs and SNVs to perform clonal
decomposition using Hidden Markov Models.
It is important to note that single allele frequencies
offer only a very limited snapshot of the tumor
phylogeny. In particular, many different trees can agree
with the same pattern of allele frequencies and only
few topological constraints exist to limit the space of
solutions (Fig. 4). Jiao et al. (2014) discuss this issue and
ﬁnd that SNVclusters can always be ordered into a linear
cascade (with the most frequent one on top and the least
frequent one at the bottom) and in a fork (unless the
sum of frequencies of the child nodes is larger than the
frequency of the parent node). Having multiple samples
can further constrain the tree topology and, for example,
predict a fork if the frequencies in the different samples
put the clones into contradictory linear orders (Jiao
et al. 2014). In summary, single allele frequencies offer
only weak evidence for tumor phylogenies. Sequencing
technologies with longer reads might alleviate these
limitations in the near future, because more reads will
carry multiple SNVs and patterns of co-occurance or
mutual exclusivity will help to reﬁne tree structure.
Phylogenetic Tree Reconstruction from CNAs
In addition to SNVs, many cancers display a
large amount of genomic rearrangements resulting
in CNAs, which provide another source of data
for inferring evolutionary relationships among cancer
genomes. Copy number proﬁles are affected by the
same challenges as SNVs, such as normal admixture
and subclonal genomic changes. Attempts to address
these issues include Sector Ploidy Proﬁling (Navin
et al. 2010), which involves macrodissection of a
physical sample into sectors followed by cell sorting
according to total DNA content, which results in
more genomically homogeneous cell populations. Copy
number proﬁles were then computed by segmenting
intensities derived from two-color aCGH microarrays.
Trees were reconstructed using distances based on
Pearson correlation between the logR values followed
by neighbor-joining tree inference (Saitou and Nei
1987). The authors found that the breast cancers
they studied could be divided into two groups, one
genetically homogeneous group, called monogenomic
tumors, andone genetically heterogeneous group, called
polygenomic tumors.
Alternatively Oesper et al. (2013) have proposed a
computational approach for subclonal decomposition
from copy number proﬁles based on genome-wide
segmented readdepth information. In the same spiritHa
et al. (2014) implemented aHiddenMarkovModel-based
approach for identiﬁcation of subclonal copy number
proﬁles.
In any case, for tree reconstruction from copy
number proﬁles the traditionally used Euclidean or
correlation distances are ill-suited. Genomic sites
affected by rearrangement events are not independent
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FIGURE 5. Phasing copy number proﬁles. While SNP arrays are
capable of determining a major and minor copy number for the two
parental alleles, their assignment (phasing) to the two actual physical
alleles A and B is unknown. Because evolutionary events happen
on the physical copies, correct phasing is essential for determining
evolutionary distances. In this example, the two major copy number
proﬁles between sample 1 and sample 2 (left) have a distance of two
events (one ampliﬁcation at position 1 and one ampliﬁcation spanning
positions 4 and 5), while the minor copy number proﬁles are identical,
yielding a total of two events between the genomes of sample 1 and
sample 2. Optimal assignment (right) to the alleles A and B reduces the
evolutionary distance to a single ampliﬁcation event spanning the ﬁrst
ﬁve genomic loci. This is also not evident from the total copy number
(the sum of major and minor) which would still require two separate
events.
and identically distributed. By the nature of the DNA
replication process all genomic rearrangement events
have a speciﬁc start and end, duplicating or deleting
all bases between those two loci (Hastings et al. 2009).
Thismechanism results in strong dependencies between
adjacent loci that are not accounted for by Euclidean
or correlation distances, because they consider all loci
independently, rather than the actual events.
To address this limitation, Letouzé et al. (2010)
proposed the TuMult method, which works on
breakpoints, that is, loci at which the copy number
changes, instead of full genomic proﬁles. Using a
novel breakpoint distance they estimate the number of
genomic events between two copy number proﬁles, and
these distances are then used for tree reconstruction.
TuMult has been applied by Sottoriva et al. (2013a)
to estimating phylogenies of glioblastoma. Like earlier
methods, TuMult does not take allele-speciﬁc copy
numbers into account.
Greenman et al. (2012) and Purdom et al. (2013)
developed related algorithms for estimating the order
of genomic rearrangement events. Although tree
reconstruction is not the primary focus of these studies,
ordering events involves solving similar problems as
for estimating evolutionary distances. For example, for
each site, the major and minor copy numbers must be
assigned to one of the twophysical alleles, that is, phased
(Fig. 5). Greenman et al. (2012) use external linkage
information that can, for example, be obtained from
HapMap and a graph-theoretical approach to ﬁnd the
most likely assignment of each copy number to either
of the two alleles. Ultimately, the method ﬁnds the most
likely clonal ordering by solving this problem over all
sampled genomes of a tumor. The phasing problem is
solved in a similar fashion by the Battenberg algorithm
(Nik-Zainal et al. 2012a).
Schwarz et al. (2014b) have recently developed
MEDICC to jointly solve the problems of phasing
and tree reconstruction using a minimum evolution
criterion. Based on ﬁnite-state transducers (Cortes et al.
2004; Schwarz et al. 2010), MEDICC computes the
minimum number of ampliﬁcation and deletion events
to transform one genomic proﬁle into another. It ﬁnds
allele-speciﬁc phasing, tree topology, and ancestral
genomes such that the total tree length, that is, the
total number of genomic events in the tree, is minimal.
In an application of this approach to a large study
of high-grade serous ovarian carcinoma, the authors
conﬁrmed the bi-partition of tumors into mono- and
polygenomic cancers and showed that this stratiﬁcation
predicts resistance development (Schwarz et al. 2014a).
Single-cell Approaches
For a small number of loci, ﬂuorescent in situ
hybridization has been used to characterize tumor
heterogeneity on a single-cell level (Almendro et al.
2014; Trinh et al. 2014) and to infer phylogenetic trees
(Chowdhury et al. 2013). On a genome-wide level,
recent years have brought great advances in single-cell
sequencing (Shapiro et al. 2013). For example,Navin et al.
(2011) used low-coverage single-nucleus sequencing to
reconstruct evolutionary histories of cancer lineages
based on CNAs. They employed conventional neighbor-
joining using a Euclidean distance metric on the
discretized integer copy number proﬁles for tree
building.Houet al. (2012)demonstrated clonal evolution
in essential thrombocythemia tumors by single-cell
whole-exome sequencing of 90 individual cells and a
population-level model of evolution, whereas Xu et al.
(2012) found no evidence for clonal subpopulations
when sequencing individual kidney cancer cells. One of
the ﬁrst statistical methods for evolutionary inference
from single-cell sequencing data by Kim and Simon
(2014) explicitly models the high single-cell sequencing
error rates and infers phylogenetic relationships as well
as orderings of mutations. Single-cell sequencing is still
in its infancy and brings its own dedicated challenges,
suchas ampliﬁcationbias, buthas thepotential to resolve
some of the limitations of current approaches, most
notably the phasing problem. In the near future, we
expect most clinical studies on intratumor diversity to
still rely on NGS of mixed samples, because of technical
challenges and cost-beneﬁt considerations.
CANCER PROGRESSION
Genetic events that drive cancer progression generally
do not occur independently of each other. Direct and
indirect interactions result from nonlinear, epistatic
ﬁtness landscapes underlying the evolutionary process
and introduce statistical dependencies among genetic
alterations. For example, Höglund et al. (2001)
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a)  Phylogenetic models
FIGURE 6. Phylogenetic versus oncogenetic models. Phylogenetic
models of tumor samples (a) and oncogenetic models of cancer drivers
(b) use the same type of data: genomic aberrations observed in patient
tumor samples. Phylogenetic models (a) use mostly genomewide data
of a small number of evolutionary-related tumor samples, either from
the samepatient or fromdifferent cloneswithin the same tumor. Tumor
progression models (b), on the other hand, generally concentrate
on a small number of aberrations observed in a larger number of
independent tumors from different patients.
analyzed cytogenetic data from 3,016 solid cancers
and observed preferential combinations of alterations
using principal component analysis suggesting distinct
evolutionary pathways. Graphical progression models
are used to estimate these dependencies (Fig. 6b).
In progression models, tumor samples from different
patients are regarded as independent realizations of
the same stochastic evolutionary process. The data is
typically cross-sectional, that is, tumors are observed
at different unknown time points. Most progression
network models are variations of Bayesian networks,
a class of directed graphical models representing
conditional independencies among random variables.
Available software for modeling cancer progression is
summarized in Table 3.
Trees with Unobserved Internal Vertices
Among the ﬁrst approaches to estimate dependencies
among cancer-driving events were distance-based
phylogenetic methods. The idea is to compute distances
between genetic events, rather than between tumors as
discussed above, and then to compute an optimal tree,
where the observed genetic alterations are represented
as the leaves of the tree. Desper et al. (2000) deﬁne the
distance between events X and Y as
−2logP(X,Y)+logP(X)+logP(Y) (13)
which quantiﬁes the deviation of the joint distribution
P(X,Y) from P(X)P(Y), the one expected under the
independence model. The authors subsequently apply
distance-based tree reconstruction methods, such as
neighbor-joining. Von Heydebreck et al. (2004) have
developed an efﬁcient maximum likelihood approach
for a probabilistic Bayesian network formulation of the
same treemodel, inwhich internalvertices correspond to
TABLE 3. Software tools implementing probabilistic graphical models for estimating cancer progression.
Model Topology LPD Constraints Noise Learning Software References
OT/HI tree discrete monotone no ML oncomodela (Desper et al. 2000;
von Heydebreck et al. 2004)
OT tree discrete monotone no MWB oncotreesb (Desper et al. 1999)
OT tree discrete monotone yes MWB oncotreec (Szabo and Boucher 2002)
HOT tree discrete monotone yes ML via SEM n.a. (Toﬁgh et al. 2011)
Mixture of OTs forest discrete monotone yes ML via SEM mtreemixd (Beerenwinkel et al. 2005b;
Beerenwinkel et al. 2005a)
Mixture of HOTs forest discrete monotone yes ML via SEM hotmixe (Toﬁgh et al. 2011)
CBN DAG discrete monotone yes ML cbnf (Beerenwinkel et al. 2007b)
CT-CBN DAG waiting time monotone no ML via EM ct-cbng (Beerenwinkel and Sullivant 2009)
Hidden CBN DAG waiting time monotone yes ML via EM, SA h-cbnh (Gerstung et al. 2009)
Bayesian CBN DAG discrete monotone yes MCMC bayes-cbni (Sakoparnig and Beerenwinkel 2012)
NAM DAG waiting time none no ML n.a. (Hjelm et al. 2006)
ON DAG discrete (semi-)mon. yes MILP diprogj (Shahrabi Farahani and Lagergren 2013)
RESIC none RE none no SM upon request (Attolini et al. 2010; Cheng et al. 2012)
Notes: OT, Oncogenetic tree; OT/HI, OT with hidden internal nodes; HOT, Hidden oncogenetic tree; CBN, Conjunctive Bayesian Network;
CT-CBN, Continuous-time CBN; NAM, Network aberration model; ON, Oncogenetic network; LPD, local probability distribution; RESIC,
Retracing the Evolutionary Steps in Cancer; DAG, directed acyclic graph; ML, maximum likelihood; EM, Expectation-Maximization algorithm;
SEM, Structural EM; MCMC, Markov chain Monte Carlo; MWB, Maximum weight branching; MILP, mixed integer linear program; RE, Rate of
evolution (Moran process); SA, Simulated annealing; SM, Simplex minimization by Nelder and Mead
ahttp://cran.r-project.org/web/packages/oncomodel/
bhttp://www.ncbi.nlm.nih.gov/CBBresearch/Schaffer/cgh.html
chttp://cran.r-project.org/web/packages/Oncotree/
dhttp://mtreemix.bioinf.mpi-inf.mpg.de/
ehttps://github.com/atoﬁgh/hotmix
fhttp://www.cbg.ethz.ch/software/cbn/
ghttp://www.cbg.ethz.ch/software/ct-cbn/
hhttp://www.cbg.ethz.ch/software/ct-cbn/
ihttp://www.cbg.ethz.ch/software/bayes-cbn/
jhttps://bitbucket.org/farahani/diprog
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hidden random variables. Although there is no obvious
interpretation of the internal vertices, these models
capture information about co-occurrences of events, and
they can help detecting preferred sequential orders of
events, speciﬁcally early events in tumor progression.
Indeed, if an event X occurs almost always before event
Y, then the leaf representing X will be close to the path
from the root of the tree to vertex representing Y.
Oncogenetic Trees
Oncogenetic tree models were introduced by Desper
et al. (1999). They describe the accumulation of
mutations under ordering constraints, which can be
represented by a tree. The root of the tree is the
wildtype without alterations. The branches at a given
node describe the set of additional mutations that
become possible when the node is mutated. Unlike the
tree models discussed above, oncogenetic trees have
no hidden internal vertices, but all vertices correspond
to observed genetic alterations. The star deﬁnes the
least restricted oncogenetic tree model, in which all
alterations are possible at any time. The most restrictive
topology is a linear chain of alterations, as in the
case of sequential accumulation of APC → KRAS →
TP53 mutations during colorectal carcinogenesis, the
ﬁrst explicit description of cancer driver dependencies
(Fearon and Vogelstein 1990). Desper et al. (1999) have
proposed an efﬁcient tree reconstruction algorithm
based on an instance of maximum weight branching, a
classical combinatorial optimization problem (Edmonds
1967; Karp 1971). Cancer progression models have been
applied to CGH data, which records losses and gains
of entire chromosome arms. For example, Jiang et al.
(2000) used both distance-based and oncogenetic tree
models to analyze dependencies among chromosomal
aberrations in clear cell renal cell carcinoma. They found
two distinct subgroups of tumors and clariﬁed that loss
of the small arm of chromosome 8 is a late event in renal
cell carcinogenesis.
The original oncogenetic treemodel fromDesper et al.
(1999) does not explicitly account for observation errors.
Szabo and Boucher (2002) have made this extension
to the model and the inference algorithm accounting
for false positive and false negative observations.
Oncogenetic trees have also been approached in the
likelihood framework and extended to mixture models.
Mixtures of oncogenetic trees provide a more ﬂexible
alternative to ﬁtting a single tree, for example, in the
presence of tumor subgroups, or alternative, mutually
exclusive evolutionary pathways (Beerenwinkel et al.
2005a). They can be estimated by a structural EM
algorithm, which, in each step, computes a maximum
weight branching. To account for observation errors,
a noise component with star topology is often used.
Tree mixtures have been used to derive the genetic
progression score, deﬁned as the expected waiting
time of the observed tumor in the model. This score
improved survival predictions in glioblastoma and
prostate cancers (Rahnenführer et al. 2005). Toﬁgh et al.
(2011) have further generalized oncogenetic tree mixture
models by introducing, for each event, a hidden random
variable indicating a possible observation error. Their
hidden-variable oncogenetic trees (HOTs) thus offer a
different error model. Global structural EM algorithms
for learning HOTs and mixtures of HOTs have been
developed.
Progression Networks
In tumor progression networks, the assumption of
a tree-like dependency structure among alterations is
dropped. General Bayesian network models have been
proposed for this purpose (Radmacher et al. 2001),
but they are often too computationally expensive to
learn from data and not straightforward to interpret
as progressions in time. A common assumption is
monotonicity, that is, for each event, all its predecessors
in the graph are required to occur before it can happen.
For example, Conjunctive Bayesian networks (CBNs)
are monotone progression networks. They generalize
oncogenetic trees and are deﬁned by a partially
ordered set of mutations (Beerenwinkel et al. 2007b).
In continuous-time CBNs, the waiting time for each
mutation is assumed to be distributed exponentially;
a genotype is deﬁned by all mutations that have
accumulated before a stopping time (Beerenwinkel and
Sullivant 2009). Additionally, the observed genotypes
may differ from the true genotypes because of
observation errors (Gerstung et al. 2009). A nested
EM algorithm is used to estimate the parameters of
both the error and waiting time processes in the
hidden CBN (H-CBN) model. The H-CBN allows for
de-noising genotypes using the maximum a posteriori
(MAP) estimates based on the progressionmodel, which
were found to improve survival predictions in renal
cell carcinoma. Gerstung et al. (2011a) applied the
H-CBN model to genetic data from three different
cancer types, and found that there is stronger evidence
for temporal dependencies among signaling pathways
than among individual genes, likely because there are
often many different ways to hit a signaling pathway.
Using the Wright–Fisher model of cancer progression
(Beerenwinkel et al. 2007a), they also showed that the
accumulation rates of alterations in the CBN model are
approximately linearly related to the ﬁtness advantages
s. Recently, a Bayesian inference scheme has been
proposed for CBNs, which allows for assessing the
full posterior probability of the partial order and the
parameters (Sakoparnig and Beerenwinkel 2012).
Hjelm et al. (2006) have proposed an extended
network aberration model (NAM), where aberrations
are grouped together. Here, events not only occur
randomly in time according to intensity parameters,
but also the stopping intensity of the process after
each event depends on the number of aberrations
grouped into the event. In addition, the strength of all
pairwise dependencies are explicitly parametrized in
this model. A heuristic ML method is developed owing
to the increased complexity of the model. More recently,
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progressionnetwork inference has been addressedusing
mixed integer linear programming. Shahrabi Farahani
and Lagergren (2013) have devised and solved such
an optimization problem for any decomposable model
score, including the likelihood score and the Bayesian
information criterion score. This approach works for
monotone as well as for semimonotone networks, where
only the presence of at least one predecessor mutation,
rather than all, is required. Attolini et al. (2010) proposed
aprogressionmodel inwhich the transitionprobabilities
between genotypes are given by a Moran process. This
method has then been extended by Cheng et al. (2012) to
also account for transitions between cell states deﬁned
by altered signaling pathways.
All progression models discussed above aim at
estimating the dependency structure among mutational
events.YounandSimon (2012)haveproposeda statistical
model for assessing the order of mutations without
estimating their full dependency structure explicitly.
Instead, they estimate the probability of each mutation
i to occur as the k-th event in tumorigenesis directly.
Although less informative about individual progression
pathways, this approach may be more powerful for
identifying early versus late mutations.
Sprouffske et al. (2011) used an agent-based model
of a colon crypt to show that using cross-sectional
data for inferring mutational order can be misleading.
They emphasize the need for integrating phylogenetic
methods based on intratumor samples to accurately
reconstruct the evolutionary history of tumors. More
generally, progression models will beneﬁt greatly from
assessing and resolving intrapatient and intratumor
diversity. Integrating these two orthogonal modeling
approaches (Fig. 6) is a major challenge for future work.
APPLICATIONS AND PERSPECTIVES
Although cancer evolution is a fascinating topic for
computational and evolutionary biologists, much of the
progress in the ﬁeld has so far been driven by the
increasing integration of research into the clinic. On the
other hand, already today, evolutionarymodeling has an
impact on the clinical management of cancer.
Clinical Applications
Several clinical applications of evolutionary methods
have been reported. Maley et al. (2006) showed that
measures of clonal diversity can predict progression
of the premalignant Barret’s esophagus to a full-
blown adenocarcinoma. In the future, this ﬁnding could
enable clinical identiﬁcation of high-risk patients that
demand immediate treatment. Evolutionary studies
can also give insight into the metastatic process and
how selection pressure shapes the metastatic genotype.
Khalique et al. (2009) demonstrated the clonal evolution
of metastases from primary epithelial ovarian cancers
using parsimony-based tree reconstruction on LOH
events. In pancreatic cancer, a particularly aggressive
malignancy, Campbell et al. (2010) identiﬁed genomic
rearrangements that dysregulate the transition from the
G1 to S phase of cell cycle and demonstrated convergent
evolution among different metastases.
Complementary to studies that focus on early
cancer development and the metastatic process,
evolutionary studies have tried to identify sources of
chemotherapy resistance. Cooke et al. (2011) showed
that genetic heterogeneity indicates poor response to
chemoradiotherapy in cervical cancer. In hereditary
ovarian carcinomas, it was subsequently shown that
secondary mutations that restore BRCA1/2 predict
chemotherapy resistance (Norquist et al. 2011). Later, an
evolutionary study of high-grade serous ovarian cancers
showed, for the ﬁrst time, a correlation between genetic
heterogeneity, patient survival, and chemotherapy
resistance, and identiﬁed subclonal NF1 deletions as
potential drivers of resistant relapse (Schwarz et al.
2014a). Similarly, subclonal driver mutations have
recently been identiﬁed that comprise risk factors for
rapid disease progression in in chronic lymphocytic
leukemia (Landau et al. 2013) and myelodysplasia
(Papaemmanuil et al. 2013).
Evolutionary modeling can play an important role
not only in supporting diagnostics and prognostics,
but also for rationalizing treatment design (Bozic et al.
2012; Hochberg et al. 2013). For example, Chmielecki
et al. (2011) use a 2-type branching process model with
constraints derived from clinical data to predict dosing
schedules of tyrosine kinase inhibitors against EGFR
mutants. They found that the optimized dosing schemes
may delay drug resistance development in lung cancer.
Outlook
Recent advancements in high-throughput molecular
proﬁling techniques allow for the assessment of the
molecular states of tumors in great detail. Cancer
genome data are collected at a large scale in many
clinical studies and in international consortia, such as
The Cancer Genome Atlas (TCGA) and the International
Cancer Genome Consortium (ICGC). Most of these
projects initially aim at characterizing the mutational
landscape of various types of cancer by sequencing the
tumors of many patients at low or moderate coverage
(Stratton et al., 2009; Vogelstein et al., 2013). These
data will be highly informative for discovering and
cataloguing common aberrations in cancer genomes
(Fig. 1) and for studying inter-tumordiversity and cancer
progression (Fig. 6).
However, cancer is not only a disease of the genome,
but also of abnormal cellular interactions in the tumor
tissue. For example, the ﬁtness of a clone depends on
its genotype and the tissue environment the cells live in.
The tissue microenvironment is a complex dynamical
system with multiple cellular components that can
inﬂuence cancer progression and evolution (Cairns
1975; Merlo et al. 2006; Lambert et al. 2011; Greaves
and Maley 2012). Cancer cells are inﬂuenced by their
tissue habitat, and reciprocally, they can remodel the
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tissue microenvironment to their competitive advantage
(Barcellos-Hoff et al. 2013). Future studies will have to
combine analyses of genetic heterogeneity with analyses
of tumor tissue architecture to account for genetic
variation and epigenetic variation of cancer cells as well
as their interactions with surrounding cells (Marusyk
et al. 2012; Barcellos-Hoff et al. 2013; Frank and Rosner
2012; Bissell andHines 2011; Cairns 1975). Someprogress
is being made in this direction by jointly analyzing
genomic data and pathological images (Yuan et al.
2012), butmost evolutionary analyses are still performed
on genetic data without any information of the tissue
environment.
Once the technological hurdles of single-cell genomic
proﬁling, such as inefﬁcient and unbiased genome
ampliﬁcation, are overcome and individual cancer
genomes can be identiﬁed reliably at a larger scale,
tumor evolution can be studied more precisely and in
greater detail. Novel and more powerful probabilistic
models for these data will be required and are already
being developed. They will need to take the spatial
dynamics of tumors into account to allow for a systems
view on cancer progression. Additionally, they will
need to account for cancer-speciﬁc properties, such as
generally nonhomogeneous rates of evolution. Cancer
often requires deactivation of DNA repair pathways
as an early driver event and in the course of clonal
evolution, more of these events will follow, giving rise to
mutatorphenotypes.Other important questions concern
cancer stem cells (Kreso and Dick 2014). Do all cancer
cells have the capability of spawning new subclones
and metastasize? Or is the metastatic potential limited
to a small number of stem cells? The answers to these
questions have important implications for the resulting
tree topology, which could be fully branched, or star-like
(Navin and Hicks 2010; Schwarz et al. 2014a).
Longitudinal sampling will pose both a challenge
and an opportunity to phylogenetic reconstructions in
cancer. Where in the traditional phylogenetics scenario
all taxa are sampled at the same time point, different
samples from biopsies before and after treatment
might call for additional, more ﬂexible evolutionary
methodology. In this context, circulating tumorDNAhas
recently received a lot of attention. It has been shown
that from tumor DNA found in the plasma of patients,
tumor load, and genetic heterogeneity of the cancer
can be inferred without the need for invasive biopsy
or surgery (Forshew et al. 2012; Dawson et al. 2013;
Murtaza et al. 2013). This opens many new possibilities
for longitudinal sampling of patients that circumvent
many of the inherent logistical and ethical complications
of traditional clinical studies.
Intra-tumor genetic heterogeneity is often portrayed
as a major challenge for successful targeted treatment.
However, evolutionary analysis of the process leading
to the observed heterogeneity could turn this perceived
weakness into a strength by tailoring treatment
speciﬁcally to the unique evolutionary scenario within
each patient. Evolutionary models will thereby play
an essential role in predicting escape mutations to
treatment before they appear. Together with targeted
therapy options, this approach will hopefully allow us
to either ultimately eradicate the cancer or permanently
restrict its growth, thus turning it into a chronic disease
with low impact on quality of life.
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